Background Previous, uncontrolled studies have suggested that first-line treatment with
gefitinib would be efficacious in selected patients with non–small-cell lung cancer. Methods In …

Background First-line pembrolizumab monotherapy improves overall and progression-free
survival in patients with untreated metastatic non-small-cell lung cancer with a programmed …

Background Osimertinib is an epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI)
that is selective for both EGFR-TKI sensitizing and T790M resistance mutations in …

The epidermal growth factor receptor (EGFR) kinase inhibitors gefitinib and erlotinib are
effective treatments for lung cancers with EGFR activating mutations, but these tumors invariably …

Purpose The results of the Iressa Pan-Asia Study (IPASS), which compared gefitinib and
carboplatin/paclitaxel in previously untreated never-smokers and light ex-smokers with …

MET amplification activates ERBB3/PI3K/AKT signaling in EGFR mutant lung cancers and
causes resistance to EGFR kinase inhibitors. We demonstrate that MET activation by its ligand…

Background The efficacy of the ALK inhibitor crizotinib as compared with standard
chemotherapy as first-line treatment for advanced ALK-positive non–small-cell lung cancer (NSCLC) …

Background In single-group studies, chromosomal rearrangements of the anaplastic lymphoma
kinase gene (ALK) have been associated with marked clinical responses to crizotinib, an …

Purpose The LUX-Lung 3 study investigated the efficacy of chemotherapy compared with
afatinib, a selective, orally bioavailable ErbB family blocker that irreversibly blocks signaling …

Background Enhancing tumor-specific T-cell immunity by inhibiting programmed death ligand
1 (PD-L1)–programmed death 1 (PD-1) signaling has shown promise in the treatment of …